90% Capital Reduction (10:1 Stock Consolidation) to Improve Financial Structure
-
Decided 90% capital reduction (10:1 stock consolidation) to cover deficit and improve financial structure
-
Consolidation of 10 common shares (face value 1,000 won) into 1 share; outstanding shares reduced from 71,523,533 to 7,152,353 (90% reduction)
-
Capital stock reduced from 71,523,533,000 won to 7,152,353,000 won (90% reduction)
-
Shareholder meeting scheduled on May 21, 2026; record date for reduction June 5, 2026; expected listing change June 30, 2026
-
Trading suspension from June 4 to June 29, 2026
-
Reduction passed by ordinary resolution, creditor objection procedure omitted
-
Fractional shares (less than 1) to be paid in cash based on closing price on the first day of changed listing
KOSDAQ Filing Information
-
Filing: Proxy Statement
-
Company: Telcon RF Pharmaceutical (200230)
-
Submission: Telcon RF Pharmaceutical. Inc.
-
Receipt: 04-29-2026